A+ | A | A- | Skip to main content |

800 years stamp

Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Friday, 12 June 2026 12:00 AM EOD	Asian-Paints2746.50	Hind-Unilever2167.55	ITC285.15	Trent2754.75	Larsen-and-Toubro4050.20	M-and-M3043.35	Reliance-Industries1292.75	Tata-Steel197.85	Titan-Company4187.05	SBI1016.90	Bharat-Electron406.55	Kotak-Mah-Bank403.35	Infosys1116.45	Bajaj-Finance918.65	Sun-PharmaInds1807.25	HDFC-Bank772.40	TCS2161.50	ICICI-Bank1340.35	Power-Grid-Corpn284.80	Maruti-Suzuki13371.25	Axis-Bank1355.55	HCL-Technologies1109.20	NTPC353.95	Bharti-Airtel1822.55	Tech-Mahindra1429.40	Adani-Ports1813.30	UltraTech-Cem11107.95	Bajaj-Finserv1689.25	Interglobe-Aviat4708.65	Eternal243.80
15 mins delay SENSEX 75,527.95 [1,695.40]	55.50 2.06%	28.15 1.32%	2.85 1.01%	42.95 1.58%	190.75 4.94%	42.15 1.40%	30.15 2.39%	-0.15 -0.08%	162.15 4.03%	16.25 1.62%	4.20 1.04%	10.25 2.61%	2.45 0.22%	48.35 5.56%	12.95 0.72%	27.80 3.73%	26.20 1.23%	22.95 1.74%	-1.85 -0.65%	277.95 2.12%	38.45 2.92%	-0.80 -0.07%	1.95 0.55%	40.40 2.27%	-35.35 -2.41%	26.00 1.45%	274.10 2.53%	44.25 2.69%	206.75 4.59%	8.55 3.63%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Dr. Reddy's Labs oncology drug Bosutinib Tablets in United States

13-Jun-26 16:55Hrs IST

The pharmaceutical major has collaborated with MSN Laboratories (MSN), a leading pharmaceutical company in India, on this product.

Dr. Reddy's holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product.

Bosutinib Tablets was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the U.S.

The Bosulif brand had U.S. sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data.

Milan Kalawadia, CEO- North America, Dr. Reddy's Laboratories, Inc. said: This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers.

With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable.

Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company had reported a 86.14% decline in consolidated net profit to Rs 220.9 crore on 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 over Q4 FY25.

The scrip shed 0.09% to end at Rs 1273.90 on the BSE on Friday.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."

A Muthoot M George Enterprise